Jesper Hallas
Professor
Research Interests
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Jesper Hallas is a Professor at the University of Southern Denmark. His research areas include drug safety surveillance, epidemiological analysis of real-world data, and the evaluation of medical treatments in relation to patient outcomes. His recent publications focus on issues such as the impact of prescription drugs during pregnancy, point-of-care testing for respiratory infections, and the analysis of medication error reports. He is based in Denmark and contributes significantly to the fields of pharmacology and public health.
Articles (27)
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Purpose We aimed to evaluate the conditions under which the sequence ratio (SR) obtained from a sequence symmetry analysis is an unbiased estimate of the true incidence rate ratio (IRR). Methods We simulated cohorts of 1 million individuals who could initiate an exposure drug and experience a very rare, rare, common, or frequent outcome of interest. The outcome rate among exposed individuals was modified by a true incidence rate ratio of 0.2, 0.5, 1.0, 2.0, and 5.0. We further evaluated scenarios where the outcome was fatal and led to immediate censoring or the outcome reduced the rate of initiation of the exposure drug. Results We found the SR to be close to unbiased for rare, common, and frequent events, except when the true IRR was 5.0 (mean SR 4.94 and 3.74 for common and frequent events). The SR was slightly biased when the outcome was very rare. When the outcome was potentially fatal, the SR was increasingly biased with an increasing probability of death. Likewise, when the outcome reduced the probability of future exposure, the SR was upwards biased. Conclusion The SR is a biased estimate of the incidence rate ratio, when the true IRR is high, the outcome has a high mortality, or when the outcome reduces the probability of future exposure.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (36)
Marie Linder
Karolinska Institutet
Per Damkier
Odense University Hospital
Jesper Hvass Schmidt
Odense University Hospital
alma b pedersen
Aarhus University
Svetlana Skurtveit
norwegian centre for addiction research (seraf) university of oslo oslo norway
Axel C.P. Diederichsen
Odense University Hospital
Lars Frost
Aarhus University
Martin Torp Rahbek
-
Morten Schmidt
Aarhus University
Lars Melholt Rasmussen
Professor
Odense Universitetshospital
Andrea Margulis
Health Solutions
Dorte Jarbøl
University of Southern Denmark
Mette Bliddal
-
Kristian Kidholm
Odense University Hospital
Jeppe Lange
Aarhus University
Helga Zoega
Scientia A/Professor
UNSW Sydney
Leena Saastamoinen
Head of Research
-
Marc Stegger
Murdoch University
Stine Hald
University of Southern Denmark
Sebrina Maj-Britt Hansen
University of Southern Denmark
Anton Pottegård
University of Southern Denmark
Louise Ladebo
Assistant Professor
University of Southern Denmark
Søren Bie Bogh
Odense University Hospital
Daniel Ward
Aalborg University
Henrik Kjærulf Jensen
Aarhus University
Lanfranco Pellesi
-
Jes S. Lindholt
-
Jesper Bo Nielsen
Head of Institute, professor
University of Southern Denmark
Espen Jimenez-Solem
Associate Professor
University of Copenhagen
Helene Kildegaard
Copenhagen University Hospital
Lars Christian Lund
-
Kirill Gromov
Copenhagen University Hospital
Rikke Søgaard
Professor
University of Southern Denmark
Morten Andersen
Københavns Universitet
Kjeld Andersen
-
Brian Cleary
Honorary Clinical Associate Professor
Royal College of Surgeons in Ireland
Make your next move.
Prepare your application
Review drafts before you send them.